Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG.